Counters add new counter Standard counter counter id : 6290370 (Hidden) id counter displays: 6290370 site ID: 4637739 Hidden tracker Counter code standard NO JAVASCRIPT Site use frames Paste this code in your HTML editor where you would like to display the counter, at the bottom of the page, in a table, div or under a menu. gdpr policy for your website

InDevR and Sino Biological collaborate to deliver multiplex analytical solutions

Sponge rat innehåll

The partnership addresses the biopharmaceutical industry’s urgent need for improved in-process and QC testing tools for the rapidly evolving application areas of mRNA vaccine and cell and gene therapy

BOULDER, CO – June 5, 2024 – InDevR, Inc., a leader in analytical solutions for vaccine-in-process and quality control testing, and Sino Biological, Inc., a biotechnology company listed on the Shenzhen stock exchange subsidiary ChiNext (SZSE: 301047), specialized in biological research reagents and related technical contract research services, today announced a new partnership to accelerate the development of multiplex assays for a broad range of vaccine, mRNA therapies, and cell and gene therapy applications.

Through this partnership, Sino Biological’s catalog of high-quality antibodies, antigens and other reagents are available for use on InDevR’s VaxArray platform. Biopharmaceutical companies around the world are currently leveraging the VaxArray Platform’s multiplex assay capabilities in vaccine testing to simplify, standardize and accelerate the development of new vaccines, optimization of existing formulations, and scale-up of manufacturing. The two companies aim to accelerate the development and deployment of multiparametric analytical tools to help researchers drive advances in mRNA, vaccine development and the rapidly evolving field of cell and gene therapy.

Since 2003, InDevR’s core focus has been on providing innovative analytical tools for the vaccine industry. “Moving forward, our goal is to leverage that expertise to address the urgent need for improved analytical tools for cell and gene therapies and mRNA vaccine testing. Our collaboration with Sino Biological, with their extraordinary breadth and depth of offering and commitment to quality, will drive new product development and enable our customers to design their own multiplex assays with ease,” said Dr. Kathy Rowlen, CEO of InDevR.

Sino Biological, an expert in the field of recombinant protein production and antibody development, is equally enthusiastic about the collaboration. “We are pleased to work with InDevR to enhance the capabilities of their VaxArray platform,” said Dr. Rob Burgess, Chief Business Officer of Sino Biological. “Our extensive range of quality reagents, combined with InDevR’s advanced analytical technology, promises to deliver superior solutions for process and quality control testing in the biopharmaceutical industry.”

About InDevR

InDevR is a leader in innovative solutions for in-process, QC and release testing of vaccines. Dedicated to improving the speed and accuracy of characterization of vaccines and other biological products, InDevR’s products and services are trusted by leading pharmaceutical companies and research institutions around the world.

About Chinese Organic

Sino Biological is an international reagent supplier and contract research service provider. The company specializes in the production of recombinant proteins and the development of antibodies. All Sino Biological products are independently developed and manufactured with a strict quality management system and contain unique bioreagents that focus on areas such as cell therapy, stem cell research and infectious disease research. In addition, Sino Biological offers contract research manufacturing services for the custom development of complete, bioactive proteins and high-affinity antibodies, among other services. For more information about Sino Biological, visit, follow the company on LinkedIn or @SinoInc on Twitter.

Forward-Looking Statements

Certain statements in this document constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These statements are based on the current expectations of InDevR and Sino Biological management and are subject to uncertainty and changing circumstances. Actual results may differ materially from those expressed in these statements due to a variety of factors over which neither InDevR nor Sino Biological has the control. InDevR and Sino Biological assume no obligation to update these forward-looking statements and do not intend to do so.

For media questions or collaboration opportunities, please contact:

InDevr, Inc.
Craig Hoechstetter
Vice President, Sales and Marketing
[email protected]

Chinese Organic, Inc.
[email protected]

Related Articles

Back to top button